Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC

Non-small-cell lung cancer takes up the majority of lung carcinoma-caused deaths. It is reported that targeting PD-1/PD-L1, a well-known immune evasion checkpoint, can eradicate tumor. Checkpoint inhibitors, such as monoclonal antibodies, are actively employed in cancer treatment. Thus, this review...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jing, Alduais, Yaser, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review (Unsolicited)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493325/
https://www.ncbi.nlm.nih.gov/pubmed/34606729
http://dx.doi.org/10.1177/09636897211041587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493325/
https://www.ncbi.nlm.nih.gov/pubmed/34606729
http://dx.doi.org/10.1177/09636897211041587

Ejemplares similares